The US government has stopped a Baltimore manufacturing plant that ruined 15 million doses of Johnson &amp; Johnson's COVID-19 vaccine from making the vaccine developed by AstraZeneca Plc.

According to a report in the New York Times, AstraZeneca on Saturday said in a statement it will work with President Joe Biden's administration to find an alternative site.

J&amp;J said in a statement that it was "assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at the Emergent BioSolutions Inc. Bayview facility."

The move by the US Department of Health and Human Services' will now render the Emergent BioSolutions facility solely devoted to making the Johnson &amp; Johnson single-dose vaccine, and is meant to avoid future mix-ups, according to the newspaper report, which cites two senior federal health official

The US government's top infectious disease doctor, Antony Fauci, had earlier said the country may not need AstraZeneca's vaccine, even if it wins approval.

<a href="https://www.wionews.com/world/fauci-says-us-may-not-need-astrazeneca-covid-vaccine-374863">Also read |&nbsp;Fauci says US may not need AstraZeneca Covid vaccine</a>

AstraZeneca has been under scanner for months now for the alleged blood clotting side effects the vaccine has had on its takers.

Some countries are restricting use of the AstraZeneca vaccine while others have resumed inoculations, as investigations into reports of rare, and sometimes severe, blood clots continue.

The European Medicines Agency (EMA), probing links between the AstraZeneca coronavirus vaccine and blood clots, have repeatedly said they found no specific risk factors, including age. They are, however, investigating further.

<a href="https://www.wionews.com/world/eu-medical-agency-again-backs-astrazeneca-covid-vaccine-374694">Also read |&nbsp;EU medical agency again backs AstraZeneca Covid vaccine</a>

The US government has stopped a Baltimore manufacturing plant that ruined 15 million doses of Johnson & Johnson's COVID-19 vaccine from making the vaccine developed by AstraZeneca Plc.

The US government has stopped a Baltimore manufacturing plant that ruined 15 million doses of Johnson & Johnson's COVID-19 vaccine from making the vaccine developed by AstraZeneca Plc. According to a report in the New York Times, AstraZeneca on Saturday said in a statement it will work with President Joe Biden's administration to find an alternative site. J&J said in a statement that it was "assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at the Emergent BioSolutions Inc. Bayview facility." The move by the US Department of Health and Human Services' will now render the Emergent BioSolutions facility solely devoted to making the Johnson & Johnson single-dose vaccine, and is meant to avoid future mix-ups, according to the newspaper report, which cites two senior federal health official The US government's top infectious disease doctor, Antony Fauci, had earlier said the country may not need AstraZeneca's vaccine, even if it wins approval. Also read | Fauci says US may not need AstraZeneca Covid vaccine AstraZeneca has been under scanner for months now for the alleged blood clotting side effects the vaccine has had on its takers. Some countries are restricting use of the AstraZeneca vaccine while others have resumed inoculations, as investigations into reports of rare, and sometimes severe, blood clots continue. The European Medicines Agency (EMA), probing links between the AstraZeneca coronavirus vaccine and blood clots, have repeatedly said they found no specific risk factors, including age. They are, however, investigating further. Also read | EU medical agency again backs AstraZeneca Covid vaccine

US stops AstraZeneca vaccine production at Baltimore plant

British regulators have identified 30 cases of rare blood clot events after the use of the AstraZeneca COVID-19 vaccine. Uk's Medicines and Healthcare products Regulatory Agency has also said that it had received no such reports of clotting events following the use of the vaccine made by Pfizer and BioNTech.

UK regulators find 30 cases of blood clot events after using AstraZeneca COVID vaccine

The United States may not need AstraZeneca’s COVID-19 vaccine, even if it wins U.S. regulatory approval, says Anthony Fauci on Friday.

'US may not need AstraZeneca Covid vaccine', says Anthony Fauci

British regulators have identified 30 cases of rare blood clot events after the use of the AstraZeneca COVID-19 vaccine. UK's Medicines and Healthcare products Regulatory Agency has also said that it had received no such reports of clotting events following the use of the vaccine made by Pfizer and BioNTech.

British regulators identifies 30 blood clot cases after use of AstraZeneca jab

European Medicines Agency (EMA) has once again reiterated its backing of the AstraZeneca COVID-19 vaccine after Germany suspended its use for people above the age of 60 years.

EMA sees 'no evidence' to restrict AstraZeneca vaccine amid suspensions

The European Union drug regulator said on Wednesday that it has not identified any "specific risk factors" of the Oxford-AstraZeneca <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus&nbsp;vaccine</a>, but is carrying out further analysis.&nbsp;

"At present, the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events," the European Medicines Agency in a statement said.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/germany-halts-use-of-astrazeneca-covid-19-vaccine-for-under-60s-374492/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

The announcement comes after some European countries have limited its use only to the elderly population.&nbsp;

The German government on Tuesday said that Oxford-AstraZeneca's vaccine will be used only for over 60-year-olds after the country's regulatory body found "very rare but very serious cases of thrombosis".&nbsp;

Also read | <a href="https://www.wionews.com/science/biontech-pfizer-say-their-covid-19-vaccine-has-100-efficacy-in-12-15-year-olds-374524">BioNTech-Pfizer say their Covid-19 vaccine has 100% efficacy in 12-15 year olds</a>

Der Spiegel magazine on Tuesday reported that Germany's medicines regulator has confirmed 31 cases of blood clots in people vaccinated with the Oxford-AstraZeneca vaccine and nearly all cases were being detected in young and middle-aged women.

Canada on Monday also halted the drug's use for people under-55s "pending further analysis".&nbsp;

In France, the vaccine can only be used by people over 55s and Spain has taken the same measure for those under-65.&nbsp;

Earlier, the World Health Organization (WHO) and the EU's health body both have shrugged off blood clot fears related to the Oxford-AstraZeneca vaccine, calling it safe to use after probes.&nbsp; 
&nbsp;

The European Union drug regulator said on Wednesday that it has not identified any "specific risk factors" of the Oxford-AstraZeneca coronavirus vaccine, but is carrying out further analysis.

The European Union drug regulator said on Wednesday that it has not identified any "specific risk factors" of the Oxford-AstraZeneca coronavirus vaccine, but is carrying out further analysis. "At present, the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events," the European Medicines Agency in a statement said. Watch | The announcement comes after some European countries have limited its use only to the elderly population. The German government on Tuesday said that Oxford-AstraZeneca's vaccine will be used only for over 60-year-olds after the country's regulatory body found "very rare but very serious cases of thrombosis". Also read | BioNTech-Pfizer say their Covid-19 vaccine has 100% efficacy in 12-15 year olds Der Spiegel magazine on Tuesday reported that Germany's medicines regulator has confirmed 31 cases of blood clots in people vaccinated with the Oxford-AstraZeneca vaccine and nearly all cases were being detected in young and middle-aged women. Canada on Monday also halted the drug's use for people under-55s "pending further analysis". In France, the vaccine can only be used by people over 55s and Spain has taken the same measure for those under-65. Earlier, the World Health Organization (WHO) and the EU's health body both have shrugged off blood clot fears related to the Oxford-AstraZeneca vaccine, calling it safe to use after probes.

EU says no age-related risk of AstraZeneca vaccine found so far

Germany is suspending routine use of the Oxford-AstraZeneca COVID-19 vaccine for people aged below 60 because of a risk of rare blood clots. The decision was taken by the country's health minister after an emergency meeting.

Germany halts use of AstraZeneca COVID-19 vaccine for under-60s

Germany is set to limit the use of AstraZeneca’s COVID-19 vaccine among people aged 60 and above following reports of a rare brain blood disorder. In addition, the country will limit usage among high-priority groups.

"We have to be able trust the vaccines," Chancellor Angela Merkel said during a press conference on Tuesday.&nbsp; "And transparency is the best way to deal with such a situation," she added.

Merkel acted on the advice of STIKO, country’s vaccine committee. After deliberation, the federal and state governments decided against using the vaccine.

People above 60 who have received one shot may get their second shot or wait until further recommendations come in by the end of April.

Also read:&nbsp;<a href="http://13.235.153.162/world/canada-to-pause-astrazeneca-covid-19-vaccine-use-for-those-under-55-374290" hreflang="en">Canada to pause AstraZeneca COVID-19 vaccine use for those under 55</a>

Earlier, STIKO suggested the jab be used only for people aged 60 and above "on the basis of available data on the occurrence of rare but very severe thromboembolic side-effects". In addition, STIKO is considering using a different shot for the second jab.

AstraZeneca responded to the claims saying that safety was its highest priority, while adding that European and UK medical agencies had failed to establish a causal relationship between the vaccine and blood clots.

Also read:&nbsp;<a href="http://13.235.153.162/world/eu-asks-astrazeneca-to-catch-up-on-covid-vaccine-deliveries-373240" hreflang="en">EU asks AstraZeneca to 'catch up' on COVID vaccine deliveries</a>

AstraZeneca on March 22 announced that its COVID-19 vaccine is 80 per cent effective against the virus among the elderly, and poses no blood clot risks. The numbers came in after phase III trials in the US, as European countries shun AstraZeneca vaccines for fears of blood clots.

Among the overall population, the vaccine was 79 per cent effective at preventing symptomatic coronavirus.&nbsp;In terms of preventing severe disease and hospitalisation, the vaccine showed 100 per cent efficacy.

The US phase III trials of the vaccines developed by AstraZeneca and Oxford University had 32,449 participants, out of whom two thirds received the jab, the company’s statement said. Out of these 20 per cent were aged 65 and above, while 60 per cent had health conditions that pose a high risk of severe case of COVID-19.

Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a hit in European countries. After reports of rare blood clots made the news, people’s confidence in the vaccine dipped especially in Spain, Germany, France, and Italy, poll data shows.

YouGov conducted the poll which found that even by late February, Europeans were wary of the AstraZeneca jab, as opposed to vaccines made by Pfizer/BioNTech and Moderna. Reports of blood clots from vaccines had severely damaged the public perception surrounding the vaccine.

Germany is set to limit the use of AstraZeneca’s COVID-19 vaccine among people aged 60 and above following reports of a rare brain blood disorder. In addition, the country will limit usage among high-priority groups.

Germany is set to limit the use of AstraZeneca’s COVID-19 vaccine among people aged 60 and above following reports of a rare brain blood disorder. In addition, the country will limit usage among high-priority groups. "We have to be able trust the vaccines," Chancellor Angela Merkel said during a press conference on Tuesday. "And transparency is the best way to deal with such a situation," she added. Merkel acted on the advice of STIKO, country’s vaccine committee. After deliberation, the federal and state governments decided against using the vaccine. People above 60 who have received one shot may get their second shot or wait until further recommendations come in by the end of April. Also read: Canada to pause AstraZeneca COVID-19 vaccine use for those under 55 Earlier, STIKO suggested the jab be used only for people aged 60 and above "on the basis of available data on the occurrence of rare but very severe thromboembolic side-effects". In addition, STIKO is considering using a different shot for the second jab. AstraZeneca responded to the claims saying that safety was its highest priority, while adding that European and UK medical agencies had failed to establish a causal relationship between the vaccine and blood clots. Also read: EU asks AstraZeneca to 'catch up' on COVID vaccine deliveries AstraZeneca on March 22 announced that its COVID-19 vaccine is 80 per cent effective against the virus among the elderly, and poses no blood clot risks. The numbers came in after phase III trials in the US, as European countries shun AstraZeneca vaccines for fears of blood clots. Among the overall population, the vaccine was 79 per cent effective at preventing symptomatic coronavirus. In terms of preventing severe disease and hospitalisation, the vaccine showed 100 per cent efficacy. The US phase III trials of the vaccines developed by AstraZeneca and Oxford University had 32,449 participants, out of whom two thirds received the jab, the company’s statement said. Out of these 20 per cent were aged 65 and above, while 60 per cent had health conditions that pose a high risk of severe case of COVID-19. Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a hit in European countries. After reports of rare blood clots made the news, people’s confidence in the vaccine dipped especially in Spain, Germany, France, and Italy, poll data shows. YouGov conducted the poll which found that even by late February, Europeans were wary of the AstraZeneca jab, as opposed to vaccines made by Pfizer/BioNTech and Moderna. Reports of blood clots from vaccines had severely damaged the public perception surrounding the vaccine.

Germany halts use of AstraZeneca vaccine for elderly amid reports of rare disorder

Canada has announced that it will halt the use of the AstraZeneca-Oxford COVID-19 vaccine for those under the age of 55. However, people over the age of 55 will continue to get the jab with 'informed consent'.

Canada suspends AstraZeneca for under 55

Canadian health officials said they would stop offering&nbsp;AstraZeneca's COVID-19 vaccine to people aged under 55 and require a new analysis of the shot's benefits and risks based on age and gender.

Manitoba and Quebec provinces were the first to heed the new National Advisory Committee on Immunization and Health (NACI) guidelines, with each region responsible for its own immunisation program.

"There is substantial uncertainty about the benefits of providing AstraZeneca vaccines to adults under 55 years of age,"&nbsp;Canada's deputy chief public health officer Howard Njoo told a news conference.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/canada-suspends-astrazeneca-for-under-55-374189/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"At this time, we are pausing the use of AstraZeneca vaccine to adults under 55 years of age, pending further risk-benefit analysis," he said.

Officials, meanwhile, urged Canadians who have received the AstraZeneca shot in the last 20 days to consult a doctor.

AstraZeneca&nbsp;said in a statement it respected NACI's decision and that it was working closely with Health Canada's assessment. The British drugmaker also reiterated that authorities in Britain, the European Union as well as the World Health Organization have found the product's benefits to significantly outweigh the risks across all adult age groups.

Njoo later noted that Canada was taking this "prudent" approach because alternative vaccines are available. Most of Canada's supply so far has come from Pfizer Inc and Moderna Inc.

Older people face a greater risk of hospitalization and death from COVID-19, and the complication seems to be rarer in that age group, NACI said, so they can be offered the vaccine "with informed consent."

Health Canada said in a statement it would add new terms and conditions to the vaccine's authorizations, including "a requirement that the manufacturers conduct a detailed assessment of the benefits and risks of the vaccine by age and sex in the Canadian context."

Health Canada said it had been in talks with&nbsp;AstraZeneca, and once it has the requested information, it "will determine if additional regulatory actions are necessary."

The NACI earlier this month urged giving AstraZeneca shots only to people aged 18 to 64, saying clinical trials hadn't included enough seniors, then revised its recommendation to include people of 65 and over after reviewing "real-world evidence" of its effectiveness in seniors.

The AstraZeneca vaccine candidate was approved for use in&nbsp;Canada&nbsp;in February, alongside Johnson &amp; Johnson, Pfizer-BioNTech and Moderna shots.

The moves follow reports from Europe of rare but serious blood clots, bleeding and in some cases death after vaccination, mainly in young women. No such cases have been reported in Canada, with about 307,000&nbsp;AstraZeneca&nbsp;doses administered.

Many European countries briefly stopped using the Anglo-Swedish firm's vaccine while investigating the blood clot incidents earlier this month. Canada continued to administer doses, arguing that the benefits of vaccination outweighed potential risks.

Nearly all countries have since resumed use of the&nbsp;AstraZeneca&nbsp;vaccine. But France broke with guidance from the European medical regulator and said on March 19 it should only be given to people aged 55 or older. France said the decision was based on evidence that the clotting affected younger people.

Canada is expecting another 1.5 million doses of the&nbsp;AstraZeneca&nbsp;vaccine this week from the United States, which has not yet authorized its use. Canada has ordered more than 20 million doses from&nbsp;AstraZeneca&nbsp;and&nbsp;Serum Institute of India.

Canadian health officials said they would stop offering AstraZeneca's COVID-19 vaccine to people aged under 55 and require a new analysis of the shot's benefits and risks based on age and gender.

Canadian health officials said they would stop offering AstraZeneca's COVID-19 vaccine to people aged under 55 and require a new analysis of the shot's benefits and risks based on age and gender. Manitoba and Quebec provinces were the first to heed the new National Advisory Committee on Immunization and Health (NACI) guidelines, with each region responsible for its own immunisation program. "There is substantial uncertainty about the benefits of providing AstraZeneca vaccines to adults under 55 years of age," Canada's deputy chief public health officer Howard Njoo told a news conference. "At this time, we are pausing the use of AstraZeneca vaccine to adults under 55 years of age, pending further risk-benefit analysis," he said. Officials, meanwhile, urged Canadians who have received the AstraZeneca shot in the last 20 days to consult a doctor. AstraZeneca said in a statement it respected NACI's decision and that it was working closely with Health Canada's assessment. The British drugmaker also reiterated that authorities in Britain, the European Union as well as the World Health Organization have found the product's benefits to significantly outweigh the risks across all adult age groups. Njoo later noted that Canada was taking this "prudent" approach because alternative vaccines are available. Most of Canada's supply so far has come from Pfizer Inc and Moderna Inc. Older people face a greater risk of hospitalization and death from COVID-19, and the complication seems to be rarer in that age group, NACI said, so they can be offered the vaccine "with informed consent." Health Canada said in a statement it would add new terms and conditions to the vaccine's authorizations, including "a requirement that the manufacturers conduct a detailed assessment of the benefits and risks of the vaccine by age and sex in the Canadian context." Health Canada said it had been in talks with AstraZeneca, and once it has the requested information, it "will determine if additional regulatory actions are necessary." The NACI earlier this month urged giving AstraZeneca shots only to people aged 18 to 64, saying clinical trials hadn't included enough seniors, then revised its recommendation to include people of 65 and over after reviewing "real-world evidence" of its effectiveness in seniors. The AstraZeneca vaccine candidate was approved for use in Canada in February, alongside Johnson & Johnson, Pfizer-BioNTech and Moderna shots. The moves follow reports from Europe of rare but serious blood clots, bleeding and in some cases death after vaccination, mainly in young women. No such cases have been reported in Canada, with about 307,000 AstraZeneca doses administered. Many European countries briefly stopped using the Anglo-Swedish firm's vaccine while investigating the blood clot incidents earlier this month. Canada continued to administer doses, arguing that the benefits of vaccination outweighed potential risks. Nearly all countries have since resumed use of the AstraZeneca vaccine. But France broke with guidance from the European medical regulator and said on March 19 it should only be given to people aged 55 or older. France said the decision was based on evidence that the clotting affected younger people. Canada is expecting another 1.5 million doses of the AstraZeneca vaccine this week from the United States, which has not yet authorized its use. Canada has ordered more than 20 million doses from AstraZeneca and Serum Institute of India.

Canada to pause AstraZeneca COVID-19 vaccine use for those under 55

European Union Chief Ursula von der Leyen said on Thursday that AstraZeneca needed to "catch up" on its COVID vaccine deliveries and could not export the vaccines out of the EU until the commitments are fulfilled.

"I think it is clear that first of all the company has to catch up, has to honour the contract it has with the European member states, before it can engage again in exporting vaccines," she told a news conference after an EU summit dominated by the bloc's struggling vaccination rollout.

These blunt words also threaten to deepen row with Britain as it is trying to secure AstraZeneca shipments from EU. This is being done to fill an abrupt hole in the supplies.

Brussels and London have both laid claim to vaccine stocks in an AstraZeneca factory in the Netherlands.

European Commission's stance of toughening rules on vaccine exports has not been received well in the UK but a joint statement by Britain and the EU said that both sides are looking to find a "win-win" solution.

(With AFP inputs)

European Union Chief Ursula von der Leyen said on Thursday that AstraZeneca needed to "catch up" on its COVID vaccine deliveries and could not export the vaccines out of the EU until the commitments are fulfilled.

European Union Chief Ursula von der Leyen said on Thursday that AstraZeneca needed to "catch up" on its COVID vaccine deliveries and could not export the vaccines out of the EU until the commitments are fulfilled. "I think it is clear that first of all the company has to catch up, has to honour the contract it has with the European member states, before it can engage again in exporting vaccines," she told a news conference after an EU summit dominated by the bloc's struggling vaccination rollout. These blunt words also threaten to deepen row with Britain as it is trying to secure AstraZeneca shipments from EU. This is being done to fill an abrupt hole in the supplies. Brussels and London have both laid claim to vaccine stocks in an AstraZeneca factory in the Netherlands. European Commission's stance of toughening rules on vaccine exports has not been received well in the UK but a joint statement by Britain and the EU said that both sides are looking to find a "win-win" solution. (With AFP inputs)

EU asks AstraZeneca to 'catch up' on COVID vaccine deliveries

<a href="https://www.wionews.com/world/north-korea-may-have-fired-ballistic-missile-into-the-sea-reports-say-372966">North Korea may have fired ballistic missile into the sea, reports say</a>

North Korea launched at least two projectiles suspected to be ballistic missiles on Thursday, officials in South Korea, Japan, and the United States said | <a href="https://www.wionews.com/world/north-korea-may-have-fired-ballistic-missile-into-the-sea-reports-say-372966">READ MORE</a>

<a href="https://www.wionews.com/world/biden-to-hold-first-press-conference-after-breaking-100-year-record-without-one-372963">Biden to hold first press conference after breaking 100-year record without one</a>

After seven weeks into his Oval Office tenure, Joe Biden will give his first formal press conference as president today, at 1:15 p.m. ET | <a href="https://www.wionews.com/world/biden-to-hold-first-press-conference-after-breaking-100-year-record-without-one-372963">READ MORE</a>

<a href="https://www.wionews.com/world/astrazeneca-says-covid-vaccine-76-effective-in-updated-us-trial-data-372964">AstraZeneca says Covid vaccine 76% effective in updated US trial data</a>

British-Swedish drugmaker AstraZeneca has revised down the efficacy figure for its two-dose Covid vaccine following a clinical trial held across the United States, Peru and Chile | <a href="https://www.wionews.com/world/astrazeneca-says-covid-vaccine-76-effective-in-updated-us-trial-data-372964">READ MORE</a>

<a href="https://www.wionews.com/entertainment/lifestyle/news-nike-faces-social-media-storm-in-china-over-xinjiang-statement-372985">Nike faces social media storm in China over Xinjiang statement</a>

Anger with Nike Inc erupted on Chinese social media late on Wednesday after China`s netizens spotted a statement from the sporting goods giant saying it was "concerned" about reports of forced labour in Xinjiang and that it does not use cotton from the region | <a href="https://www.wionews.com/entertainment/lifestyle/news-nike-faces-social-media-storm-in-china-over-xinjiang-statement-372985">READ MORE</a>

<a href="https://www.wionews.com/sports/olympics-torch-relay-starts-in-fukushima-as-north-korea-launches-missiles-372983">Olympics torch relay starts in Fukushima as North Korea launches missiles</a>

The Olympic torch relay set off from Fukushima on Thursday, beginning a four-month countdown to the Summer Games in Tokyo, delayed from 2020 and the first-ever organised during a global pandemic | <a href="https://www.wionews.com/sports/olympics-torch-relay-starts-in-fukushima-as-north-korea-launches-missiles-372983">READ MORE</a>

<a href="https://www.wionews.com/world/from-prison-camp-to-ballot-box-north-korean-defector-seeks-british-election-win-372981">From prison camp to ballot box: North Korean defector seeks British election win</a>

Sixteen years after she was left to die unremembered outside a labour camp in North Korea, Jihyun Park will enter the British political history books if she wins office in local elections this May | <a href="https://www.wionews.com/world/from-prison-camp-to-ballot-box-north-korean-defector-seeks-british-election-win-372981">READ MORE</a>

<a href="https://www.wionews.com/entertainment/prince-harry-takes-role-fighting-avalanche-of-misinformation-372973">Prince Harry takes role fighting 'avalanche of misinformation'</a>

Britain's Prince Harry -- who is often at war with the British press -- was on Wednesday announced as a commissioner for a US study into misinformation online | <a href="https://www.wionews.com/entertainment/prince-harry-takes-role-fighting-avalanche-of-misinformation-372973">READ MORE</a>

North Korea may have fired ballistic missile into the sea, reports say North Korea launched at least two projectiles suspected to be ballistic missiles on Thursday, officials in South Korea, Japan, and the United States said | READ MORE Biden to hold first press conference after breaking 100-year record without one After seven weeks into his Oval Office tenure, Joe Biden will give his first formal press conference as president today, at 1:15 p.

North Korea may have fired ballistic missile into the sea, reports say North Korea launched at least two projectiles suspected to be ballistic missiles on Thursday, officials in South Korea, Japan, and the United States said | READ MORE Biden to hold first press conference after breaking 100-year record without one After seven weeks into his Oval Office tenure, Joe Biden will give his first formal press conference as president today, at 1:15 p.m. ET | READ MORE AstraZeneca says Covid vaccine 76% effective in updated US trial data British-Swedish drugmaker AstraZeneca has revised down the efficacy figure for its two-dose Covid vaccine following a clinical trial held across the United States, Peru and Chile | READ MORE Nike faces social media storm in China over Xinjiang statement Anger with Nike Inc erupted on Chinese social media late on Wednesday after China`s netizens spotted a statement from the sporting goods giant saying it was "concerned" about reports of forced labour in Xinjiang and that it does not use cotton from the region | READ MORE Olympics torch relay starts in Fukushima as North Korea launches missiles The Olympic torch relay set off from Fukushima on Thursday, beginning a four-month countdown to the Summer Games in Tokyo, delayed from 2020 and the first-ever organised during a global pandemic | READ MORE From prison camp to ballot box: North Korean defector seeks British election win Sixteen years after she was left to die unremembered outside a labour camp in North Korea, Jihyun Park will enter the British political history books if she wins office in local elections this May | READ MORE Prince Harry takes role fighting 'avalanche of misinformation' Britain's Prince Harry -- who is often at war with the British press -- was on Wednesday announced as a commissioner for a US study into misinformation online | READ MORE

Morning news brief: N Korea fires missile, AstraZeneca updates vaccine efficacy, and more

India has put a temporary hold on all major exports of the AstraZeneca COVID-19 vaccines made by the SII to meet domestic demand as infections rise.

Coronavirus Update: India is facing a a surge in COVID-19 cases

British-Swedish drugmaker AstraZeneca has revised down the efficacy figure for its two-dose Covid vaccine following a clinical trial held across the United States, Peru and Chile.

The company now says its vaccine is 76 per cent effective rather than 79 per cent effective at preventing any kind of symptomatic Covid.&nbsp;The vaccine has been dogged by questions over its effectiveness and possible side-effects.

This month, more than a dozen countries temporarily suspended giving out the vaccine after reports linked it to a rare blood clotting disorder in a very small number of people. The European Union's drug regulator, however, said last week the vaccine was clearly safe, but people remain sceptical about its safety.

The updated 76 per cent efficacy rate compares with rates of about 95 per cent for vaccines from Pfizer/BioNTech and Moderna.

US health officials earlier in the week publically rebuked the drugmaker for using "outdated information" when calculating that the vaccine was 79 per cent effective.

AstraZeneca reiterated on Wednesday that the shot, developed with Oxford University, was 100 per cent effective against severe or critical forms of the disease. It also said the vaccine showed 86 per cent efficacy in adults 65 years and older.

The latest trial data was based on 190 infections and 32,449 participants in the United States, Chile and Peru, as compared to the earlier interim data -- 141 infections through February 17.

The AstraZeneca vaccine is, however, seen as crucial in tackling the spread of COVID-19 across the globe, not just due to limited vaccine supply but also because it is easier and cheaper to transport than rival shots. It has been granted conditional marketing or emergency use authorisation in more than 70 countries.

British-Swedish drugmaker AstraZeneca has revised down the efficacy figure for its two-dose Covid vaccine following a clinical trial held across the United States, Peru and Chile.

British-Swedish drugmaker AstraZeneca has revised down the efficacy figure for its two-dose Covid vaccine following a clinical trial held across the United States, Peru and Chile. The company now says its vaccine is 76 per cent effective rather than 79 per cent effective at preventing any kind of symptomatic Covid. The vaccine has been dogged by questions over its effectiveness and possible side-effects. This month, more than a dozen countries temporarily suspended giving out the vaccine after reports linked it to a rare blood clotting disorder in a very small number of people. The European Union's drug regulator, however, said last week the vaccine was clearly safe, but people remain sceptical about its safety. The updated 76 per cent efficacy rate compares with rates of about 95 per cent for vaccines from Pfizer/BioNTech and Moderna. US health officials earlier in the week publically rebuked the drugmaker for using "outdated information" when calculating that the vaccine was 79 per cent effective. AstraZeneca reiterated on Wednesday that the shot, developed with Oxford University, was 100 per cent effective against severe or critical forms of the disease. It also said the vaccine showed 86 per cent efficacy in adults 65 years and older. The latest trial data was based on 190 infections and 32,449 participants in the United States, Chile and Peru, as compared to the earlier interim data -- 141 infections through February 17. The AstraZeneca vaccine is, however, seen as crucial in tackling the spread of COVID-19 across the globe, not just due to limited vaccine supply but also because it is easier and cheaper to transport than rival shots. It has been granted conditional marketing or emergency use authorisation in more than 70 countries.

AstraZeneca says Covid vaccine 76% effective in updated US trial data

A stockpile of 29 million doses of AstraZeneca’s COVID-19 vaccine that were found languishing in a facility in Italy became the new flash point on Wednesday in the conflict between the pharmaceutical company and the European Union, as the bloc prepared to unveil stringent export restrictions primarily meant to stop drugmakers from sending doses abroad.

Italian authorities found the vaccines in a site visit, European Union officials said, at a factory near Rome that is contracted to fill and finish COVID-19 vaccine vials for AstraZeneca.

Italian authorities went to the site after receiving an alert from the European Commission, which found a discrepancy between what the company said it was producing in European Union facilities, and what the facilities themselves were reporting.

The presence of so many doses raised suspicions that the pharmaceutical company was trying to find a way to export them to Britain or elsewhere, something the bloc has demanded that AstraZeneca stop doing until the company fulfills its promises for deliveries.

The European Union was meant to receive more than 100 million vaccine doses from AstraZeneca in the first quarter of this year, but has received only 16.6 million. The supply shortage has helped to derail vaccination efforts across the 27 member countries and contributed to embarrassingly slow inoculation rates on the continent.

What has most irked the European Union is that AstraZeneca has been consistently delivering on its contract with Britain while letting the bloc take the brunt of its production failures that have diminished supplies. AstraZeneca has denied it has violated its EU contract. The bloc took the first step last week to litigate the issue by activating an amicable dispute mechanism with AstraZeneca, but there is no indication either party intends to take it to court.

The bloc tried to force AstraZeneca to deliver more doses by introducing a system of export authorizations on Feb. 1, but only one AstraZeneca shipment, a small batch headed to Australia, has been blocked since that came into force.

On Wednesday, the European Union introduced a stricter export-control plan that aims to crack down on exports, as the bloc fears AstraZeneca deliveries will also disappoint in the second quarter as the bloc confronts a third wave of infections and extended lockdowns.

EU officials said there was no evidence that the stockpile in Italy, first reported by the Italian daily La Stampa, was bound for Britain. They said the company, when confronted about the doses, said that 16 million doses were bound for the EU market and 13 million to countries under the Covax initiative that aims to get doses to poorer nations. Those latter exports would be exempt from EU controls, as they are deemed to be of humanitarian nature.

AstraZeneca did not immediately respond to a request for comment.

The officials said they had asked AstraZeneca for additional information about where the active ingredient in the vaccine vials found in Italy had been manufactured — a question aimed at forcing the company to provide more information about its supply chain and production capacity.

For AstraZeneca, the dispute over the Italian doses was the latest in a series of communications blunders with health officials on both sides of the Atlantic that have soured the company’s relationship with several governments.

Some American officials learned about a snag in the company’s clinical trials last year from the news media. The company’s U.S. trial was paused for nearly seven weeks last fall, in part because AstraZeneca was slow to provide U.S. regulators with evidence that the vaccine had not caused a neurological illness. (Investigators later concluded the symptoms were not linked to the vaccine.)

But analysts believe that some of AstraZeneca’s manufacturing difficulties are also a reflection of the company’s ambitious global distribution plans. It had intended to make as many as three billion doses this year, in part by contracting its manufacturing to plants all over the world. Other vaccine makers, by contrast, are relying on only a few facilities.

That global network of factories, analysts said, had the potential to create complications in the company’s supply chain, though it is also part of what has made the vaccine so critical to the global vaccination effort.

A stockpile of 29 million doses of AstraZeneca’s COVID-19 vaccine that were found languishing in a facility in Italy became the new flash point on Wednesday in the conflict between the pharmaceutical company and the European Union, as the bloc prepared to unveil stringent export restrictions primarily meant to stop drugmakers from sending doses abroad.

A stockpile of 29 million doses of AstraZeneca’s COVID-19 vaccine that were found languishing in a facility in Italy became the new flash point on Wednesday in the conflict between the pharmaceutical company and the European Union, as the bloc prepared to unveil stringent export restrictions primarily meant to stop drugmakers from sending doses abroad. Italian authorities found the vaccines in a site visit, European Union officials said, at a factory near Rome that is contracted to fill and finish COVID-19 vaccine vials for AstraZeneca. Italian authorities went to the site after receiving an alert from the European Commission, which found a discrepancy between what the company said it was producing in European Union facilities, and what the facilities themselves were reporting. The presence of so many doses raised suspicions that the pharmaceutical company was trying to find a way to export them to Britain or elsewhere, something the bloc has demanded that AstraZeneca stop doing until the company fulfills its promises for deliveries. The European Union was meant to receive more than 100 million vaccine doses from AstraZeneca in the first quarter of this year, but has received only 16.6 million. The supply shortage has helped to derail vaccination efforts across the 27 member countries and contributed to embarrassingly slow inoculation rates on the continent. What has most irked the European Union is that AstraZeneca has been consistently delivering on its contract with Britain while letting the bloc take the brunt of its production failures that have diminished supplies. AstraZeneca has denied it has violated its EU contract. The bloc took the first step last week to litigate the issue by activating an amicable dispute mechanism with AstraZeneca, but there is no indication either party intends to take it to court. The bloc tried to force AstraZeneca to deliver more doses by introducing a system of export authorizations on Feb. 1, but only one AstraZeneca shipment, a small batch headed to Australia, has been blocked since that came into force. On Wednesday, the European Union introduced a stricter export-control plan that aims to crack down on exports, as the bloc fears AstraZeneca deliveries will also disappoint in the second quarter as the bloc confronts a third wave of infections and extended lockdowns. EU officials said there was no evidence that the stockpile in Italy, first reported by the Italian daily La Stampa, was bound for Britain. They said the company, when confronted about the doses, said that 16 million doses were bound for the EU market and 13 million to countries under the Covax initiative that aims to get doses to poorer nations. Those latter exports would be exempt from EU controls, as they are deemed to be of humanitarian nature. AstraZeneca did not immediately respond to a request for comment. The officials said they had asked AstraZeneca for additional information about where the active ingredient in the vaccine vials found in Italy had been manufactured — a question aimed at forcing the company to provide more information about its supply chain and production capacity. For AstraZeneca, the dispute over the Italian doses was the latest in a series of communications blunders with health officials on both sides of the Atlantic that have soured the company’s relationship with several governments. Some American officials learned about a snag in the company’s clinical trials last year from the news media. The company’s U.S. trial was paused for nearly seven weeks last fall, in part because AstraZeneca was slow to provide U.S. regulators with evidence that the vaccine had not caused a neurological illness. (Investigators later concluded the symptoms were not linked to the vaccine.) But analysts believe that some of AstraZeneca’s manufacturing difficulties are also a reflection of the company’s ambitious global distribution plans. It had intended to make as many as three billion doses this year, in part by contracting its manufacturing to plants all over the world. Other vaccine makers, by contrast, are relying on only a few facilities. That global network of factories, analysts said, had the potential to create complications in the company’s supply chain, though it is also part of what has made the vaccine so critical to the global vaccination effort.

Cache of 29 Million AstraZeneca doses in Italy raises EU suspicions

&nbsp;French authorities have launched an investigation into the death of a 26-year-old who passed away a few days after he received a shot of the <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine.</a>

The 26-year-old was a medical student who died on March 18 in Nantes, 10 days after receiving a jab of AstraZeneca’s coronavirus vaccine.

Also read |&nbsp;<a href="https://www.wionews.com/world/french-prez-promises-faster-vaccine-roll-out-as-infections-explode-372556" hreflang="en">French Prez promises faster vaccine roll-out as infections 'explode'&nbsp;</a>

While an interrogation has been launched into the matter, the authorities have stressed that no link has been established yet between the death of the medical student and the AstraZeneca jab.

The authorities had carried out an autopsy on him a day after his death but the public prosecutor in Nantes, Pierre Sennes, said that “it was necessary to carry out further tests to determine the causes and circumstances of his death”.

Also read |&nbsp;<a href="https://www.wionews.com/world/astrazeneca-to-release-more-data-after-us-raises-questions-on-shots-potential-372554" hreflang="en">AstraZeneca to release more data after US raises questions on shot's potential</a>

For now, the ANSM national drug safety watchdog has been informed about the death of the medical student “as part of our increased monitoring of thrombosis cases”, but stressed that no link has been established yet with AstraZeneca.

The watchdog also first stated the deceased’s age as 24, which the prosecutor’s office later corrected to be 26. “This death is the subject of an in-depth clinical investigation,” it said in a statement.

This news has come five days after France and several other European countries resumed AstraZeneca’s coronavirus vaccines. Earlier, several EU nations had suspended the use of the AstraZeneca vaccine over reports of blood clots in a handful of people who had received a jab of this vaccine.

The WHO said reported rates of so-called thromboembolic events after Covid-19 vaccines were in line with the usual number of people suffering these conditions.

French authorities have launched an investigation into the death of a 26-year-old who passed away a few days after he received a shot of the coronavirus vaccine.

French authorities have launched an investigation into the death of a 26-year-old who passed away a few days after he received a shot of the coronavirus vaccine. The 26-year-old was a medical student who died on March 18 in Nantes, 10 days after receiving a jab of AstraZeneca’s coronavirus vaccine. Also read | French Prez promises faster vaccine roll-out as infections 'explode' While an interrogation has been launched into the matter, the authorities have stressed that no link has been established yet between the death of the medical student and the AstraZeneca jab. The authorities had carried out an autopsy on him a day after his death but the public prosecutor in Nantes, Pierre Sennes, said that “it was necessary to carry out further tests to determine the causes and circumstances of his death”. Also read | AstraZeneca to release more data after US raises questions on shot's potential For now, the ANSM national drug safety watchdog has been informed about the death of the medical student “as part of our increased monitoring of thrombosis cases”, but stressed that no link has been established yet with AstraZeneca. The watchdog also first stated the deceased’s age as 24, which the prosecutor’s office later corrected to be 26. “This death is the subject of an in-depth clinical investigation,” it said in a statement. This news has come five days after France and several other European countries resumed AstraZeneca’s coronavirus vaccines. Earlier, several EU nations had suspended the use of the AstraZeneca vaccine over reports of blood clots in a handful of people who had received a jab of this vaccine. The WHO said reported rates of so-called thromboembolic events after Covid-19 vaccines were in line with the usual number of people suffering these conditions.

France launches investigation into death of student who got AstraZeneca vaccine

Pharmaceutical company AstraZeneca said Tuesday it will release further data "within 48 hours" on trials in the United States of its Covid-19 vaccine, after health officials raised concerns about initial information disclosed.

"We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis," the company said in a statement.

"We intend to issue results of the primary analysis within 48 hours."

Also read|&nbsp;<a href="https://www.wionews.com/world/astrazeneca-may-have-included-outdated-data-in-vaccine-trials-us-regulator-372491" hreflang="en">AstraZeneca may have included 'outdated' data in vaccine trials: US regulator</a>

AstraZeneca&nbsp;may have released outdated information on its latest COVID-19 vaccine trial, giving an "incomplete" picture of its efficacy, a leading US&nbsp;health agency said on Tuesday, casting doubt on the shot's potential US&nbsp;rollout and plunging its developers, once again, into controversy.

The surprise public rebuke from federal health officials comes just one day after interim data from the drugmaker showed better-than-expected results from the US&nbsp;trial. That had been seen as a scientific counter to concerns that have dogged the shot over its effectiveness and possible side effects.

The vaccine, developed with Oxford University, was 79 per cent effective in preventing symptomatic illness in the large trial that also took place in Chile and Peru, according to the data. It was also 100 per cent&nbsp;effective against severe or critical forms of the disease and hospitalisation, and posed no increased risk of blood clots.

The Data Safety Monitoring Board (DSMB), an independent committee overseeing the trial, has "expressed concern that&nbsp;AstraZeneca&nbsp;may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the US&nbsp;National Institute of Allergy and Infectious Diseases (NIAID) said in a statement released after midnight in the United States.

"We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible," it said, adding that the DSMB had informed&nbsp;AstraZeneca&nbsp;of its concerns.

AstraZeneca's shares were down 1.2 per cent&nbsp;in midmorning trade.

The statement raises fresh questions about the vaccine's efficacy as it is being administered in dozens of countries worldwide and clouds the timeline for its emergency use authorization in the United States.

"This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines," Peter Kremsner, from the University Hospital in Tuebingen, Germany.

Rival vaccines from Pfizer and Moderna that use so-called mRNA technology produced efficacy rates of around 95% each, far above the 50% benchmark set by global regulators.

The DSMB is organised by NIAID, and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study. NIAID is headed by U.S. infectious diseases expert Anthony Fauci and is part of the National Institutes of Health.

"DSMB externalisations of concerns are deeply unusual for multinational pharma companies and suggest an extraordinary high level of friction between the DSMB and the sponsor," Citi analysts said in a note.

Doubts raised

Hailed as a milestone in the fight against the COVID-19 pandemic when it first emerged as a vaccine contender, the&nbsp;AstraZeneca&nbsp;shot has faced questions since late last year when the drugmaker and Oxford University published data with different efficacy readings due to a measurement error.

Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference.

Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people.

The European Union's drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained sceptical about its safety.

Fauci, who also serves as chief medical advisor to US&nbsp;President Joe Biden, said on Monday the US&nbsp;trial found no indication at all of the rare blood clots and the statement from the NIAID didn't raise questions about the trial's findings regarding blood clotting.

The latest data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants.

Analysts had noted&nbsp;AstraZeneca's achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries.

Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene &amp; Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent infections which may include new variants and thus lower protection rates.

"The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case."

The&nbsp;AstraZeneca&nbsp;vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots.

It has been granted conditional marketing or emergency use authorization in more than 70 countries. Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea's President Moon Jae-in who received it on Tuesday.

Pharmaceutical company AstraZeneca said Tuesday it will release further data "within 48 hours" on trials in the United States of its Covid-19 vaccine, after health officials raised concerns about initial information disclosed.

Pharmaceutical company AstraZeneca said Tuesday it will release further data "within 48 hours" on trials in the United States of its Covid-19 vaccine, after health officials raised concerns about initial information disclosed. "We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis," the company said in a statement. "We intend to issue results of the primary analysis within 48 hours." Also read| AstraZeneca may have included 'outdated' data in vaccine trials: US regulator AstraZeneca may have released outdated information on its latest COVID-19 vaccine trial, giving an "incomplete" picture of its efficacy, a leading US health agency said on Tuesday, casting doubt on the shot's potential US rollout and plunging its developers, once again, into controversy. The surprise public rebuke from federal health officials comes just one day after interim data from the drugmaker showed better-than-expected results from the US trial. That had been seen as a scientific counter to concerns that have dogged the shot over its effectiveness and possible side effects. The vaccine, developed with Oxford University, was 79 per cent effective in preventing symptomatic illness in the large trial that also took place in Chile and Peru, according to the data. It was also 100 per cent effective against severe or critical forms of the disease and hospitalisation, and posed no increased risk of blood clots. The Data Safety Monitoring Board (DSMB), an independent committee overseeing the trial, has "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the US National Institute of Allergy and Infectious Diseases (NIAID) said in a statement released after midnight in the United States. "We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible," it said, adding that the DSMB had informed AstraZeneca of its concerns. AstraZeneca's shares were down 1.2 per cent in midmorning trade. The statement raises fresh questions about the vaccine's efficacy as it is being administered in dozens of countries worldwide and clouds the timeline for its emergency use authorization in the United States. "This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines," Peter Kremsner, from the University Hospital in Tuebingen, Germany. Rival vaccines from Pfizer and Moderna that use so-called mRNA technology produced efficacy rates of around 95% each, far above the 50% benchmark set by global regulators. The DSMB is organised by NIAID, and its role is to provide study oversight and evaluate clinical data to ensure safe and ethical conduct of the study. NIAID is headed by U.S. infectious diseases expert Anthony Fauci and is part of the National Institutes of Health. "DSMB externalisations of concerns are deeply unusual for multinational pharma companies and suggest an extraordinary high level of friction between the DSMB and the sponsor," Citi analysts said in a note. Doubts raised Hailed as a milestone in the fight against the COVID-19 pandemic when it first emerged as a vaccine contender, the AstraZeneca shot has faced questions since late last year when the drugmaker and Oxford University published data with different efficacy readings due to a measurement error. Later analysis suggested the dosing interval rather than the amount of dose administered was responsible for the difference. Confidence in the vaccine took a further hit this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot after reports linked it to a rare blood clotting disorder in a very small number of people. The European Union's drug regulator said last week it was safe but an opinion poll on Monday showed Europeans remained sceptical about its safety. Fauci, who also serves as chief medical advisor to US President Joe Biden, said on Monday the US trial found no indication at all of the rare blood clots and the statement from the NIAID didn't raise questions about the trial's findings regarding blood clotting. The latest data, which has yet to be reviewed by independent researchers, was based on 141 infections among 32,449 participants. Analysts had noted AstraZeneca's achievement of producing strong trial data against a backdrop of more infectious variants spreading in the United States and other countries. Stephen Evans, a pharmacoepidemiology professor at London School of Hygiene & Tropical Medicine, said the up-to-date data request may have to do with efficacy readings from recent infections which may include new variants and thus lower protection rates. "The other vaccines may also show such reduced efficacy and we don’t know by how much. It does not leave me concerned particularly unless they had found a safety issue that was being hidden, which does not appear to be the case." The AstraZeneca vaccine is seen as crucial in tackling the spread of COVID-19 across the globe because it is easier and cheaper to transport than rival shots. It has been granted conditional marketing or emergency use authorization in more than 70 countries. Many countries are relying heavily on it to end the pandemic, and several state leaders have taken the shot to boost confidence in the vaccine including South Korea's President Moon Jae-in who received it on Tuesday.

AstraZeneca to release more data after US raises questions on shot's potential

In a fresh set back for AstraZeneca, the National Institute of Allergy and Infectious Diseases (NIAID) in the US said that AstraZeneca may have included out-of-date information during trials of its COVID-19 vaccine.

US Agency: AstraZeneca may have included outdated data

According to the US National Institute of Allergy and Infectious Diseases (NIAID), <a href="https://www.wionews.com/world/no-risk-of-blood-clots-vaccine-100-effective-against-severe-coronavirus-astrazeneca-372252">AstraZeneca</a><a href="https://www.wionews.com/world/no-risk-of-blood-clots-vaccine-100-effective-against-severe-coronavirus-astrazeneca-372252"> </a>may have provided an incomplete view of efficacy data for&nbsp;its COVID-19 vaccine from its trial in the United States.

Watch:

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/no-pork-in-our-vaccine-clarifies-astrazeneca-as-indonesia-raises-concern-372168/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"The Data Safety Monitoring Board (DSMB), an independent committee overseeing the trial, has expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," NIAID said in a statement.&nbsp;

NIAID is headed by US infectious diseases expert Anthony Fauci and is part of the National Institutes of Health with the AstraZeneca vaccine under scanner by health officials.

The vaccine developed by Oxford University is 80 per cent effective against the virus among the elderly, and poses no blood clot risks, the company had said on Tuesday.

German Chancellor Angela Merkel while announcing a five-day lockdown in the country had said she backed the EU Commission President Ursula von der Leyen's decision to ban AstraZeneca vaccines produced in the bloc from being exported unless it delivers more of the 90 million doses it agreed to supply in the first quarter of 2021.&nbsp;

"I support Commission President Ursula von der Leyen," Merkel said, adding, "We have a problem with <a href="https://www.wionews.com/world/astrazeneca-clarifies-its-vaccine-has-no-pork-derived-ingredients-372044">AstraZeneca</a>."

However, according to British pollsters YouGov, a majority of people in the biggest EU states view the AstraZeneca vaccine as unsafe.

According to the US National Institute of Allergy and Infectious Diseases (NIAID), AstraZeneca may have provided an incomplete view of efficacy data for its COVID-19 vaccine from its trial in the United States.

According to the US National Institute of Allergy and Infectious Diseases (NIAID), AstraZeneca may have provided an incomplete view of efficacy data for its COVID-19 vaccine from its trial in the United States. Watch: "The Data Safety Monitoring Board (DSMB), an independent committee overseeing the trial, has expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," NIAID said in a statement. NIAID is headed by US infectious diseases expert Anthony Fauci and is part of the National Institutes of Health with the AstraZeneca vaccine under scanner by health officials. The vaccine developed by Oxford University is 80 per cent effective against the virus among the elderly, and poses no blood clot risks, the company had said on Tuesday. German Chancellor Angela Merkel while announcing a five-day lockdown in the country had said she backed the EU Commission President Ursula von der Leyen's decision to ban AstraZeneca vaccines produced in the bloc from being exported unless it delivers more of the 90 million doses it agreed to supply in the first quarter of 2021. "I support Commission President Ursula von der Leyen," Merkel said, adding, "We have a problem with AstraZeneca." However, according to British pollsters YouGov, a majority of people in the biggest EU states view the AstraZeneca vaccine as unsafe.

AstraZeneca may have included 'outdated' data in vaccine trials: US regulator

AstraZeneca has said its COVID-19 vaccine does not contain any pork-derived ingredients. AstraZeneca's Indonesia director Rizman Abudaeri said, “At all stages of the production process, this virus vector vaccine does not use nor come in contact with pork-derived products or other animal products.”

'No pork in our vaccine', clarifies AstraZeneca as Indonesia raises concern

Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a hit in European countries. After reports of rare blood clots made the news, people’s confidence in the vaccine dipped especially in Spain, Germany, France, and Italy, poll data shows.

YouGov conducted the poll which found that even by late February, Europeans were wary of the AstraZeneca jab, as opposed to vaccines made by Pfizer/BioNTech and Moderna. Reports of blood clots from vaccines had severely damaged the public perception surrounding the vaccine.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/covid-19-vaccine-european-union-drug-regulator-says-astrazeneca-jab-is-safe-371559/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Over the last two weeks, 13 European countries halted the use of AstraZeneca’s COVID-19 vaccine, which was developed in collaboration with Oxford University.

On Thursday, the European Medicines Agency conducted a review and said that the vaccine was safe and effective, and not directly linked to blood clots. Since then, many countries have resumed its use. Even then, the European regulator did not completely rule out any potential link to blood clots known as cerebral venous sinus thrombosis or CVST.

Also read:&nbsp;<a href="http://13.235.153.162/world/astrazeneca-clarifies-its-vaccine-has-no-pork-derived-ingredients-372044" hreflang="en">AstraZeneca clarifies its vaccine has no pork-derived ingredients</a>

The poll took into account 8,000 people across seven European countries between March 12 and 18 and found that people in France, Germany, Spain, and Italy where people now see the vaccine as unsafe.

Also read:&nbsp;<a href="http://13.235.153.162/world/two-cases-of-blood-clots-reported-after-astrazeneca-shot-in-denmark-371914" hreflang="en">Two cases of blood clots reported after AstraZeneca shot in Denmark</a>

The vaccine made by AstraZeneca was already unpopular, and now continues to dip in the eyes of people. 55 per cent Germans said that the vaccine is unsafe. In France, 61 per cent said that the vaccine remains unsafe, while in Italy and Spain 36 per cent and 38 per cent respectively deem the jab unsafe.

It is only in Britain that the blood clot concern had no effect on the vaccine’s rep, where 77 per cent people believe the shot is safe. In addition, 79 per cent Britons believe Pfizer is safe for use.

Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a hit in European countries. After reports of rare blood clots made the news, people’s confidence in the vaccine dipped especially in Spain, Germany, France, and Italy, poll data shows.

Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a hit in European countries. After reports of rare blood clots made the news, people’s confidence in the vaccine dipped especially in Spain, Germany, France, and Italy, poll data shows. YouGov conducted the poll which found that even by late February, Europeans were wary of the AstraZeneca jab, as opposed to vaccines made by Pfizer/BioNTech and Moderna. Reports of blood clots from vaccines had severely damaged the public perception surrounding the vaccine. Over the last two weeks, 13 European countries halted the use of AstraZeneca’s COVID-19 vaccine, which was developed in collaboration with Oxford University. On Thursday, the European Medicines Agency conducted a review and said that the vaccine was safe and effective, and not directly linked to blood clots. Since then, many countries have resumed its use. Even then, the European regulator did not completely rule out any potential link to blood clots known as cerebral venous sinus thrombosis or CVST. Also read: AstraZeneca clarifies its vaccine has no pork-derived ingredients The poll took into account 8,000 people across seven European countries between March 12 and 18 and found that people in France, Germany, Spain, and Italy where people now see the vaccine as unsafe. Also read: Two cases of blood clots reported after AstraZeneca shot in Denmark The vaccine made by AstraZeneca was already unpopular, and now continues to dip in the eyes of people. 55 per cent Germans said that the vaccine is unsafe. In France, 61 per cent said that the vaccine remains unsafe, while in Italy and Spain 36 per cent and 38 per cent respectively deem the jab unsafe. It is only in Britain that the blood clot concern had no effect on the vaccine’s rep, where 77 per cent people believe the shot is safe. In addition, 79 per cent Britons believe Pfizer is safe for use.

Public faith in AstraZeneca's COVID-19 vaccine across Europe dips: Poll

AstraZeneca on Monday announced that its COVID-19 vaccine is 80 per cent effective against the virus among the elderly, and poses no blood clot risks. The numbers came in after phase III trials in the US, as European countries shun AstraZeneca vaccines for fears of blood clots.

Among the overall population, the vaccine was 79 per cent effective at preventing symptomatic coronavirus.&nbsp;In terms of preventing severe disease and hospitalisation, the vaccine showed 100 per cent efficacy.

The US phase III trials of the vaccines developed by AstraZeneca and Oxford University had 32,449 participants, out of whom two thirds received the jab, the company’s statement said. Out of these 20 per cent were aged 65 and above, while 60 per cent had health conditions that pose a high risk of severe case of COVID-19.

Also read: P<a href="http://13.235.153.162/world/public-faith-in-astrazenecas-covid-19-vaccine-across-europe-dips-poll-372147" hreflang="en">ublic faith in AstraZeneca's COVID-19 vaccine across Europe dips: Poll</a>

"These findings reconfirm previous results observed in AZD1222 trials across all adult populations but it's exciting to see similar efficacy results in people over 65 for the first time," wrote Ann Falsey, a professor of medicine at the University of Rochester School of Medicine, who also led the trials. 
 
"This analysis validates the AstraZeneca Covid-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus”, the statement added.

In addition, no risks of clots was found among 21,583 participants who had received at least one dose.

Also read:&nbsp;<a href="http://13.235.153.162/world/astrazeneca-clarifies-its-vaccine-has-no-pork-derived-ingredients-372044" hreflang="en">AstraZeneca clarifies its vaccine has no pork-derived ingredients</a> 
 
Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a hit in European countries. After reports of rare blood clots made the news, people’s confidence in the vaccine dipped especially in Spain, Germany, France, and Italy, poll data shows.

YouGov conducted the poll which found that even by late February, Europeans were wary of the AstraZeneca jab, as opposed to vaccines made by Pfizer/BioNTech and Moderna. Reports of blood clots from vaccines had severely damaged the public perception surrounding the vaccine.

AstraZeneca on Monday announced that its COVID-19 vaccine is 80 per cent effective against the virus among the elderly, and poses no blood clot risks. The numbers came in after phase III trials in the US, as European countries shun AstraZeneca vaccines for fears of blood clots.

AstraZeneca on Monday announced that its COVID-19 vaccine is 80 per cent effective against the virus among the elderly, and poses no blood clot risks. The numbers came in after phase III trials in the US, as European countries shun AstraZeneca vaccines for fears of blood clots. Among the overall population, the vaccine was 79 per cent effective at preventing symptomatic coronavirus. In terms of preventing severe disease and hospitalisation, the vaccine showed 100 per cent efficacy. The US phase III trials of the vaccines developed by AstraZeneca and Oxford University had 32,449 participants, out of whom two thirds received the jab, the company’s statement said. Out of these 20 per cent were aged 65 and above, while 60 per cent had health conditions that pose a high risk of severe case of COVID-19. Also read: Public faith in AstraZeneca's COVID-19 vaccine across Europe dips: Poll "These findings reconfirm previous results observed in AZD1222 trials across all adult populations but it's exciting to see similar efficacy results in people over 65 for the first time," wrote Ann Falsey, a professor of medicine at the University of Rochester School of Medicine, who also led the trials. "This analysis validates the AstraZeneca Covid-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus”, the statement added. In addition, no risks of clots was found among 21,583 participants who had received at least one dose. Also read: AstraZeneca clarifies its vaccine has no pork-derived ingredients Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a hit in European countries. After reports of rare blood clots made the news, people’s confidence in the vaccine dipped especially in Spain, Germany, France, and Italy, poll data shows. YouGov conducted the poll which found that even by late February, Europeans were wary of the AstraZeneca jab, as opposed to vaccines made by Pfizer/BioNTech and Moderna. Reports of blood clots from vaccines had severely damaged the public perception surrounding the vaccine.

No risk of blood clots, vaccine 100% effective against severe coronavirus: AstraZeneca

astrazeneca

Astrazeneca, News on Astrazeneca, stories on Astrazeneca, articles on Astrazeneca, Astrazeneca stories at Wion, Astrazeneca news, Astrazeneca latest news